PAF
MCID: PRT058
MIFTS: 66

Pure Autonomic Failure (PAF)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pure Autonomic Failure

MalaCards integrated aliases for Pure Autonomic Failure:

Name: Pure Autonomic Failure 54 60 56 74
Orthostatic Hypotension 54 26 55 30 17
Idiopathic Orthostatic Hypotension 54 60 74
Bradbury-Eggleston Syndrome 54 55 60
Postural Hypotension 26 55
Bradbury Eggleston Syndrome 54
Pure Idiopatic Dysautonomia 60
Hypotension, Orthostatic 26
Hypotension Orthostatic 56
Hypotension, Postural 26
Pure Dysautonomia 60
Paf 60

Characteristics:

Orphanet epidemiological data:

60
pure autonomic failure
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

ICD10 34 I95.1
MESH via Orphanet 46 C544351 D054970
ICD10 via Orphanet 35 G90.3
UMLS via Orphanet 75 C0393911 C2931939
Orphanet 60 ORPHA441

Summaries for Pure Autonomic Failure

NINDS : 55 Orthostatic hypotension is a sudden fall in blood pressure that occurs when a person assumes a standing position. It is due to a lesion of the baroreflex loop, which senses a change in blood pressure and adjusts heart rate and activates sympathetic nerve system fibers to cause the blood vessels to narrow and correct blood pressure. It may also be caused by hypovolemia (a decreased amount of blood in the body), resulting from the excessive use of diuretics, vasodilators, or other types of drugs, dehydration, or prolonged bed rest. The disorder may be associated with Addison's disease, diabetes, and certain neurological disorders including Multiple System Atrophy with Orthostatic Hypotension (formerly known as Shy-Drager syndrome), autonomic system neuropathies, and other dysautonomias. Symptoms, which generally occur after sudden standing, include dizziness, lightheadedness, blurred vision, and syncope (temporary loss of consciousness).

MalaCards based summary : Pure Autonomic Failure, also known as orthostatic hypotension, is related to multiple system atrophy 1 and amyloidosis, hereditary, transthyretin-related. An important gene associated with Pure Autonomic Failure is DBH (Dopamine Beta-Hydroxylase), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Circadian entrainment. The drugs Naltrexone and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, heart and brain, and related phenotypes are anhidrosis and orthostatic hypotension

Genetics Home Reference : 26 Orthostatic hypotension is a drop in blood pressure that occurs when moving from a laying down (supine) position to a standing (upright) position. The word "orthostasis" means to stand up, so the condition is defined as low blood pressure (hypotension) that occurs upon standing.

NIH Rare Diseases : 54 Pure autonomic failure is characterized by generalized autonomic failure without central nervous system (brain or spinal cord) involvement. The autonomic nervous system is the part of our bodies that controls involuntary actions, such as the widening or narrowing of our blood vessels. Failure of this system can cause a variety of symptoms. The most common symptom of pure autonomic failure is orthostatic hypotension. Other symptoms may include decreased sweating, heat intolerance, inability to empty the bladder, erectile dysfunction, incontinence or constipation, and pupil changes. The cause of this condition is usually unknown.

Wikipedia : 77 Pure autonomic failure (PAF) is a form of dysautonomia that first occurs in middle age or later in life;... more...

Related Diseases for Pure Autonomic Failure

Diseases related to Pure Autonomic Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 33.0 DBH SNCA TH
2 amyloidosis, hereditary, transthyretin-related 32.7 DBH TTR
3 syncope 30.8 GNB3 NPPA
4 pulmonary edema 30.4 ACE NPPA REN
5 movement disease 30.2 DDC SNCA TH
6 congestive heart failure 30.1 ACE EPO NPPA REN
7 synucleinopathy 30.1 DDC MAOB SNCA TH
8 rem sleep behavior disorder 30.0 ACHE SNCA
9 cerebrovascular disease 29.9 ACE ACHE REN
10 pheochromocytoma 29.9 DBH DDC MAOB REN TH
11 chronic kidney failure 29.6 ACE EPO NPPA REN TTR
12 kidney disease 29.5 ACE EPO NPPA REN TTR
13 myocardial infarction 29.4 ACE GNB3 NPPA PDE5A REN
14 hypertension, essential 29.1 ACE DBH GNB3 NEDD4L NPPA REN
15 parkinson disease, late-onset 29.0 ACHE DBH DDC MAOA MAOB SNCA
16 orthostatic hypotension 2 12.8
17 multiple system atrophy with orthostatic hypotension 12.6
18 orthostatic hypotensive disorder, streeten type 12.6
19 orthostatic hypotension 1 12.5
20 dopamine beta-hydroxylase deficiency 11.7
21 primary orthostatic hypotension 11.7
22 autoimmune autonomic ganglionopathy 11.6
23 dysautonomia 11.5
24 platelet-activating factor acetylhydrolase deficiency 11.3
25 achalasia-addisonianism-alacrima syndrome 11.2
26 syncope, familial vasovagal 11.2
27 autonomic peripheral neuropathy 11.2
28 neuropathy, hereditary sensory and autonomic, type iii 11.2
29 brain dopamine-serotonin vesicular transport disease 11.1
30 neuropathy - hereditary 11.1
31 orthostatic intolerance 11.0
32 postural orthostatic tachycardia syndrome 10.9
33 spinal cord injury 10.6
34 neuropathy 10.5
35 autonomic neuropathy 10.4
36 hereditary dystonia 10.4 DBH TH
37 gastroesophageal reflux 10.4
38 renal artery obstruction 10.4 ACE REN
39 rere-related disorders 10.4
40 depression 10.4
41 hypertension, diastolic 10.3 ACE REN
42 supratentorial primitive neuroectodermal tumor 10.3 DDC TH
43 hypertensive retinopathy 10.3 ACE REN
44 orthostatic proteinuria 10.3 ACE REN
45 malignant essential hypertension 10.3 ACE REN
46 chronic fatigue syndrome 10.3
47 anterolateral myocardial infarction 10.3 ACE NPPA
48 anuria 10.3 ACE REN
49 pernicious anemia 10.3
50 aging 10.3

Graphical network of the top 20 diseases related to Pure Autonomic Failure:



Diseases related to Pure Autonomic Failure

Symptoms & Phenotypes for Pure Autonomic Failure

Human phenotypes related to Pure Autonomic Failure:

60 33 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000970
2 orthostatic hypotension 60 33 hallmark (90%) Very frequent (99-80%) HP:0001278
3 abnormality of circulating catecholamine level 60 33 hallmark (90%) Very frequent (99-80%) HP:0012099
4 constipation 60 33 frequent (33%) Frequent (79-30%) HP:0002019
5 urinary incontinence 60 33 frequent (33%) Frequent (79-30%) HP:0000020
6 syncope 60 33 frequent (33%) Frequent (79-30%) HP:0001279
7 dysuria 60 33 frequent (33%) Frequent (79-30%) HP:0100518
8 impotence 60 33 occasional (7.5%) Occasional (29-5%) HP:0000802
9 dysautonomia 60 Very frequent (99-80%)
10 constitutional symptom 60 Very frequent (99-80%)

MGI Mouse Phenotypes related to Pure Autonomic Failure:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ACE ACHE DBH DDC EPO MAOA
2 cardiovascular system MP:0005385 10.11 ACE DBH DDC EPO MAOA NEDD4L
3 behavior/neurological MP:0005386 10.1 ACE ACHE DBH DDC MAOA MAOB
4 mortality/aging MP:0010768 9.96 ACE ACHE DBH DDC EPO GNB3
5 nervous system MP:0003631 9.85 ACHE DBH DDC GNB3 MAOA MAOB
6 renal/urinary system MP:0005367 9.56 ACE DDC MAOB NEDD4L NPPA REN
7 vision/eye MP:0005391 9.1 ACHE DBH DDC GNB3 TH TTR

Drugs & Therapeutics for Pure Autonomic Failure

Drugs for Pure Autonomic Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
2
Ethanol Approved Phase 4 64-17-5 702
3
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
5
Droxidopa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23651-95-8 443940
6
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 1 58-93-5 3639
7
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
8
Losartan Approved Phase 4,Phase 1 114798-26-4 3961
9
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
10
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1 59-92-7 6047
11
Mirabegron Approved Phase 4,Phase 2 223673-61-8 9865528
12
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
16
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
17
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
18
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
19
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
20
Celecoxib Approved, Investigational Phase 4,Phase 1 169590-42-5 2662
21
Methylphenidate Approved, Investigational Phase 4,Phase 1 113-45-1 4158
22
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106133-20-4 129211
23
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
24
Diazoxide Approved Phase 4 364-98-7 3019
25
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
26
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
27
Silodosin Approved Phase 4,Phase 3 160970-54-7
28
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
31 Narcotic Antagonists Phase 4,Phase 2
32 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1
41 Bromides Phase 4,Phase 2,Phase 1
42 Anticonvulsants Phase 4,Phase 2,Phase 1
43 Cholinergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
44 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1 101-26-8
45 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 diuretics Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 263)
# Name Status NCT ID Phase Drugs
1 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
2 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
3 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
4 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
5 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
6 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
7 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
8 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
9 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
10 Mirabegron in Parkinson Disease and Impaired Cognition Completed NCT02536976 Phase 4 mirabegron;Placebo
11 AMISH : Aprovel for Management of Isolated Systolic Hypertension Completed NCT00264212 Phase 4 irbesartan and irbesartan-hydrochlorothiazide
12 Adjuvant Analgesic Effects of Low Dose Tramadol/Acetaminophen Combination After Open Gynaecological Surgery Completed NCT00942565 Phase 4 tramadol/acetaminophen;acetaminophen
13 Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc Completed NCT00853840 Phase 4 Maraviroc;Vardenafil;Maraviroc;Placebo
14 A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients Completed NCT00406848 Phase 4 duloxetine hydrochloride;placebo
15 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
16 Moxonidine for Prevention of Post-ablation AFib Recurrences Completed NCT01791699 Phase 4 Moxonidine;Placebo
17 Short-term Prednisone to Treat STA Study(SPTSS) Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
18 Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) Recruiting NCT03608163 Phase 4 Naloxone;Diazoxide;Placebo (for Naloxone);Placebo (for Diazoxide)
19 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
20 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
21 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
22 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Recruiting NCT03229174 Phase 4 Droxidopa;Placebo
23 TQL-block for Laparoscopic Hemicolectomy Recruiting NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
24 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
25 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
26 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4 Methylphenidate;Methylphenidate;Placebo 10;Placebo 20
27 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
28 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
29 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
30 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
31 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
32 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
33 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
34 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3 Midodrine;Placebo
35 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
36 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3 Methylprednisolone;Isotonic Sodium Chloride
37 Exhaled Levels of Nitric Oxide Completed NCT00753948 Phase 2, Phase 3 N-Nitro L-arginine-methylester (L-NAME)
38 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3 Gadoxetic Acid Disodium (Primovist, BAY86-4873)
39 Deambulatory Epidural During the Labour Completed NCT02264834 Phase 3 Levobupivacaine 0.1% + Sufentanil 0.2µg/ml;Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
40 A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
41 Prevention of Low Blood Pressure in Persons With Tetraplegia Completed NCT00237770 Phase 2, Phase 3 N-Nitro L-arginine-methylester (L-NAME)
42 Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301) Completed NCT00446524 Phase 3 Valsartan + Amlodipine besilate
43 LEPU Renal Denervation System for Resistant Hypertension Completed NCT02536326 Phase 3
44 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
45 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
46 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
47 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
48 Caffeine as a Therapy for Parkinson's Disease Completed NCT01738178 Phase 3 Caffeine;Placebo
49 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 TD-9855;Placebo
50 Clinical Effect Durability of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03829657 Phase 3 TD-9855;Placebo

Search NIH Clinical Center for Pure Autonomic Failure

Genetic Tests for Pure Autonomic Failure

Genetic tests related to Pure Autonomic Failure:

# Genetic test Affiliating Genes
1 Orthostatic Hypotension 30

Anatomical Context for Pure Autonomic Failure

MalaCards organs/tissues related to Pure Autonomic Failure:

42
Spinal Cord, Heart, Brain, Testes, Liver, Skin, Kidney

Publications for Pure Autonomic Failure

Articles related to Pure Autonomic Failure:

(show top 50) (show all 1520)
# Title Authors Year
1
Heart Rate Variability in Spinal Cord Injury: asymptomatic orthostatic hypotension is a confounding variable. ( 30904574 )
2019
2
Relationships between orthostatic hypotension, frailty, falling and mortality in elderly care home residents. ( 30866845 )
2019
3
Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. ( 30571543 )
2019
4
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease. ( 30627953 )
2019
5
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. ( 30730771 )
2019
6
Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension. ( 30798661 )
2019
7
Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. ( 30882602 )
2019
8
Orthostatic Hypotension and Cognitive Function: Cross-sectional Results From the ELSA-Brasil Study. ( 29579161 )
2019
9
Orthostatic hypotension: is it a predictor of total and cardiovascular mortality in the elderly? ( 30640870 )
2019
10
Association of Orthostatic Hypotension Timing with Clinical Events in Adults with Diabetes and Hypertension: Results from the ACCORD Trial. ( 30715100 )
2019
11
Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. ( 30825549 )
2019
12
Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. ( 30900378 )
2019
13
Trouble Concentrating is an Easily Overlooked Symptom of Orthostatic Hypotension in Early Parkinson's Disease. ( 30909249 )
2019
14
Hypotensive Drugs and Syncope Due to Orthostatic Hypotension in Older Adults with Dementia (Syncope and Dementia Study). ( 29897099 )
2018
15
Impaired cortical autonomic responses during sympathetic activation in Neurogenic Orthostatic Hypotension characterized by post-ganglionic autonomic dysfunction. ( 29901433 )
2018
16
Does sympathetic dysfunction occur before denervation in pure autonomic failure? ( 29162745 )
2018
17
Sympathetic neurograms showing characteristics of both muscle and skin sympathetic nerve activity in a case with pure autonomic failure. ( 29313154 )
2018
18
Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. ( 29569329 )
2018
19
The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30006412 )
2018
20
Third-degree atrioventricular block followed by syncope, labile hypertension, and orthostatic hypotension in a patient with nasopharyngeal cancer: baroreflex failure. ( 30038845 )
2018
21
Long-Lasting Orthostatic Hypotension and Constipation After Celiac Plexus Block; A Case Report. ( 29868459 )
2018
22
The association between orthostatic hypotension and dementia: A meta-analysis of prospective cohort studies. ( 30247788 )
2018
23
Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30045960 )
2018
24
Pure Autonomic Failure with Asymptomatic Hypertensive Urgency: A Case Report and Literature Review. ( 30687067 )
2018
25
Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa. ( 28114866 )
2018
26
Initial orthostatic hypotension among patients with unexplained syncope: An overlooked diagnosis? ( 30223355 )
2018
27
Initial orthostatic hypotension: A common cause of syncope but uncommonly overlooked. ( 30049490 )
2018
28
Cardiovascular risk after hospitalisation for unexplained syncope and orthostatic hypotension. ( 28775101 )
2018
29
Atherosclerosis of the carotid bulb is associated with the severity of orthostatic hypotension in non-diabetic adult patients: a cross-sectional study. ( 29672186 )
2018
30
Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases. ( 29080629 )
2018
31
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. ( 30637284 )
2018
32
Skin Nerve Phosphorylated α-Synuclein Deposits in Parkinson Disease With Orthostatic Hypotension. ( 30137426 )
2018
33
Orthostatic hypotension in Parkinson disease: Impact on health care utilization. ( 29195729 )
2018
34
Orthostatic Hypotension as a Prodromal Marker of α-Synucleinopathies-Reply. ( 30105350 )
2018
35
Orthostatic Hypotension as a Prodromal Marker of α-Synucleinopathies. ( 30105358 )
2018
36
Correction to: Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. ( 29185076 )
2018
37
A patient with autonomic imbalance: Treating symptomatic neurogenic orthostatic hypotension. ( 29757831 )
2018
38
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. ( 29972032 )
2018
39
Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. ( 30144800 )
2018
40
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. ( 30229336 )
2018
41
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. ( 30232253 )
2018
42
Impaired cortical autonomic responses during sympathetic activation in neurogenic orthostatic hypotension characterized by postganglionic autonomic dysfunction. ( 30332348 )
2018
43
Validation of the new diagnostic tests for neurogenic orthostatic hypotension. ( 30341958 )
2018
44
A validated test for neurogenic orthostatic hypotension at the bedside. ( 30341962 )
2018
45
Cerebellar impairment during an orthostatic challenge in patients with neurogenic orthostatic hypotension. ( 30527385 )
2018
46
Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension. ( 30535274 )
2018
47
Orthostatic Hypotension and Associated Factors among Home Care Clients Aged 75 Years or Older - A Population-Based Study. ( 29300435 )
2018
48
Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome. ( 29343526 )
2018
49
Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - reply. ( 29356263 )
2018
50
Orthostatic Hypotension and Symptoms in the AASK Trial. ( 29370333 )
2018

Variations for Pure Autonomic Failure

Expression for Pure Autonomic Failure

Search GEO for disease gene expression data for Pure Autonomic Failure.

Pathways for Pure Autonomic Failure

Pathways related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 DDC GNB3 MAOA MAOB NPPA SNCA
2
Show member pathways
12.87 ACHE DDC GNB3 MAOA MAOB TH
3 12.41 DBH DDC GNB3 SNCA TH
4
Show member pathways
12.1 ACE ACHE GNB3 REN
5 12.02 DDC GNB3 MAOA TH
6
Show member pathways
11.8 DDC MAOA MAOB TH
7 11.77 DDC GNB3 MAOA MAOB
8
Show member pathways
11.7 DDC MAOA MAOB
9 11.65 DDC SNCA TH
10 11.63 DBH DDC MAOA TH
11
Show member pathways
11.43 DBH DDC MAOA MAOB TH
12
Show member pathways
11.27 DBH DDC TH
13
Show member pathways
11.19 ACHE DBH MAOA TH
14 11.14 MAOB SNCA TH
15 11.08 DDC TH
16 11.04 DDC MAOA
17
Show member pathways
11 ACHE MAOA
18
Show member pathways
10.74 MAOA MAOB
19
Show member pathways
10.67 MAOA MAOB
20 10.58 ACHE DDC TH
21 10.4 DDC MAOA MAOB TH
22
Show member pathways
10.36 ACHE DBH DDC MAOA TH

GO Terms for Pure Autonomic Failure

Cellular components related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ACHE DBH EPO NPPA REN
2 synaptic vesicle GO:0008021 9.33 DDC SNCA TH
3 extracellular space GO:0005615 9.23 ACE ACHE DBH EPO NPPA REN

Biological processes related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.98 DBH MAOA MAOB SNCA TH
2 response to drug GO:0042493 9.86 MAOB REN SNCA TH
3 response to hypoxia GO:0001666 9.81 EPO NPPA TH
4 response to lipopolysaccharide GO:0032496 9.72 EPO MAOB REN SNCA TH
5 cellular response to drug GO:0035690 9.69 DDC REN TH
6 regulation of blood pressure GO:0008217 9.67 ACE GNB3 NPPA REN
7 response to electrical stimulus GO:0051602 9.63 EPO TH
8 positive regulation of endocytosis GO:0045807 9.62 NEDD4L SNCA
9 response to immobilization stress GO:0035902 9.62 REN TH
10 response to corticosterone GO:0051412 9.61 MAOB TH
11 response to metal ion GO:0010038 9.61 NEDD4L TH
12 multicellular organism aging GO:0010259 9.6 DDC TH
13 synaptic transmission, dopaminergic GO:0001963 9.59 SNCA TH
14 amyloid-beta metabolic process GO:0050435 9.58 ACE REN
15 neurotransmitter biosynthetic process GO:0042136 9.57 ACHE TH
16 angiotensin maturation GO:0002003 9.55 ACE REN
17 cellular response to alkaloid GO:0071312 9.54 DDC TH
18 response to salt stress GO:0009651 9.52 EPO TH
19 norepinephrine biosynthetic process GO:0042421 9.49 DBH TH
20 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.48 DDC TH
21 response to pyrethroid GO:0046684 9.46 DDC TH
22 isoquinoline alkaloid metabolic process GO:0033076 9.43 DDC TH
23 dopamine biosynthetic process GO:0042416 9.43 DDC SNCA TH
24 phytoalexin metabolic process GO:0052314 9.4 DDC TH
25 neurotransmitter catabolic process GO:0042135 9.33 ACHE MAOA MAOB
26 dopamine catabolic process GO:0042420 9.13 DBH MAOA MAOB
27 catecholamine biosynthetic process GO:0042423 8.8 DBH DDC TH

Molecular functions related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.35 DBH MAOA MAOB SNCA TH
2 hormone activity GO:0005179 9.33 EPO NPPA TTR
3 ferrous iron binding GO:0008198 9.32 SNCA TH
4 amino acid binding GO:0016597 9.26 DDC TH
5 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Pure Autonomic Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....